abstract |
The present invention designs and synthesizes a new class of uracil-benzothiazole NS5B RdRp inhibitors with a general formula (1): The uracil-benzothiazole NS5B RdRp inhibitor provided by the present invention has better anti-1b genotype hepatitis C virus replicon (HCV-1b) activity in vitro, the raw materials required for the synthesis of the compound of the present invention are easily available, and the route design is reasonable. The reaction conditions are mild, the yield of each step is high, the operation is simple, and it is suitable for industrial production; and as a new type of NS5B RdRp inhibitor, it is expected to provide a new drug option for the clinical treatment of HCV. |